ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Angiotech Pharmaceuticals has formed a license and research pact with CombinatoRx under which it will get access to CombinatoRx's library of more than 2 million combinations of known pharmaceuticals. Angiotech will apply them to its own therapies that combine drugs with medical devices and biomaterials. Angiotech will pay CombinatoRx $27 million up front and invest $15 million in the firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter